Ortho Biotech Products, L.P. today announced that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the combination of DOXIL(R) (doxorubicin HCl liposome injection) and Taxotere(R) (docetaxel)* for the treatment of women with advanced breast cancer who have received prior anthracycline treatment.
The details can be read here.
No comments:
Post a Comment